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Abstract
Background: Bone size (BS) variation is under strong genetic control and plays an important role
in determining bone strength and fracture risk. Recently, a genome-wide association study
identified polymorphisms associated with hip BS variation in the PLCL1 (phospholipase c-like 1)
locus. Carriers of the major A allele of the most significant polymorphism, rs7595412, have around
17% larger hip BS than non-carriers. We therefore hypothesized that this polymorphism may also
influence postmenopausal complications.
Methods: The effects of rs7595412 on hip BS, bone mineral density (BMD), vertebral fractures,
serum Crosslaps and osteocalcin levels were analyzed in 1,191 postmenopausal Danish women.
Results: This polymorphism had no influence on hip and spine BS as well as on femur and spine
BMD. Women carrying at least one copy of the A allele had lower levels of serum osteocalcin as
compared with those homozygous for the G allele (p = 0.03) whereas no effect on serum Crosslaps
was detected. Furthermore, women homozygous for the A allele were more affected by vertebral
fractures than those carrying at least one copy of the G allele (p = 0.04).
Conclusions:  In postmenopausal women, our results suggest that the PLCL1  rs7595412
polymorphism has no obvious effect on hip BS or BMD but may be nominally associated with
increased proportion of vertebral fracture and increased levels of osteocalcin.
Background
Osteoporosis is as a skeletal disorder characterized by
compromised bone strength predisposing a person to an
increased risk of fracture [1]. Bone mineral density (BMD)
is commonly used to diagnose osteoporosis and to predict
individual fracture risk [2-4]. Recent genome-wide studies
based on hip BMD identified novel susceptibility genes
for osteoporosis [5,6]. Besides BMD, a growing body of
evidence suggested that bone size (BS) per se also plays an
important role in determining bone strength and fracture
risk [7-9]. Women not only lose bone density after meno-
pause but also have an increase in skeletal size as a result
of periosteal apposition [10]. Previous studies showed
that women with hip fractures have larger hip BS [11-20].
Bone must indeed be flexible since it must be able to
absorb energy by deforming, to shorten and widen when
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compressed, and to lengthen and narrow in tension with-
out cracking [21]. Previous studies have demonstrated
that BS variation is under strong genetic control, with her-
itability greater than 50% [9,22-25]. Moreover, segrega-
tion analyses have suggested that at least one major gene
for BS variation exists in Caucasians [26-28] and in Chi-
nese [29]. Candidate genes have been reported to influ-
ence hip BS [30-32]. However, these studies have
presented conflicting data, due in part to small sample
size and differences in the genetic background of control
and case subjects [33]. Recently, the first genome-wide
association study to search for novel genes underlying hip
BS variation was conducted [34]. Four SNPs associated
with hip BS in the PLCL1  locus had or approached
genome-wide significance level in women. PLCL1
encodes an inositol 1,4,5-trisphosphate (IP3) binding
protein that can inhibit IP3 mediated calcium signaling
[35], an important pathway that regulates the response of
bone cells to mechanical signals [36,37]. The most signif-
icant SNP, rs7595412, located in intron 3, achieved a p
value of 3.72 × 10-7. Carriers of the major A allele have
around 5 cm2 or 17% larger hip BS than non-carriers. In
the present study, we analyzed the effect of rs7595412 on




Clinical characteristics of the 1,191 studied individuals
were presented in Table 1. The study population consisted
of postmenopausal women, from the Prospective Epide-
miological Risk Factor study living in the Aalborg area in
Denmark [38]. The subjects were recruited by question-
naire surveys offering a screening examination for assess-
ment of skeletal and cardiovascular status. This
subpopulation was selected based on those whose BMD
and body composition were measured by the same DXA
scanner [39,40]. The population characteristics were not
statistically significant from the total PERF population
indicating that the results reported herein are generally
applicable to elderly Caucasian women 60-85 years old
[39]. All participating women signed an approved consent
form, and the study was carried out in accordance with the
Helsinki Declaration II and the European Standards for
Good Clinical Practice. The Ethical Committee of Copen-
hagen County approved the study protocol.
Quantitative trait measures
Women underwent a thorough examination. Height and
weight were measured to the closest 0.1 cm and 0.1 kg,
respectively, to calculate BMI (weight in kilograms
divided by the square of height in meters). BMD at the dis-
tal forearm was measured by a DTX200 arm scanner
(Osteometer MediTech, Rødovre, Denmark). BMD at the
lumbar spine L1-L4, total hip, and femoral neck was
measured by a Hologic QDR4500 scanner (software ver-
sion 9.03D; Hologic, Waltham, MA, USA). The hip BS was
measured as total bone area (cm2) calculated as the sum
of the areas of neck, trochanteric, and intertrochanteric
regions as measured by DXA and the spine BS (cm2) as the
sum of the area of L1-L4. The bone formation marker of
osteocalcin was measured by the Elecsys N-MID Osteocal-
cin assay, and the bone resorption marker of the C-termi-
nal telopeptide of collagen type I by the Elecsys CTx assay
(Roche, Basel, Switzerland). For these analyses, serum
samples were collected in the morning after an overnight
fasting period to exclude diurnal variation and the effect
of meal. Lateral X-rays of the thoracic and lumbar spine
were obtained using standard X-ray equipment. Vertebral
deformities from T4 to L4 were assessed by digital meas-
urements of morphologic changes using the Image Pro
Image Analyzer software (version 4.5 for Windows; Media
Cybernetics, Silver Spring, MD, USA). The ratio of the
anterior and posterior heights of each vertebral body was
determined digitally, and a difference of >20% between
the anterior and posterior edges was considered as a radi-
ographic vertebral fracture. None of the fractures were
caused by a traffic accident. Hip fractures were based on
self-reported information from a questionnaire.
Genotyping
The rs7595412 SNP was genotyped using an AOD (assay
on demand) kit (Applied Biosystems). The PCR was per-
formed with a GeneAmp 9700 PCR system. The condi-
tions for the TaqMan reaction were 95°C for 10 s and 40
cycles of 92°C for 15 s, 60°C for 1 min, and 15°C for 5 s.
Allelic discrimination was performed through capillary
electrophoresis analysis, using an Applied Biosystems
3730xl DNA analyzer and GeneMapper3.7 software. The
genotypes were determined with an ABI PRISM 7900 HT
sequence detection system. There was a 98% genotyping
Table 1: Clinical characteristics of the studied postmenopausal 
Danish women
N1 , 1 9 1
BMI (kg/m2) 26.0 ± 3.6
Age (years) 70 ± 5
Gender Only women
Hip Bone Size (cm2) 36.5 ± 3.6
Spine Bone Size (cm2) 58.3 ± 5.3
Bone Mineral Density (g/cm2)
Distal part of the arm 0.36 ± 0.08
Femur Neck 0.67 ± 0.10
Total Femur 0.79 ± 0.12
Total Spine 0.88 ± 0.15
Serum Crosslaps (ng/ml)# 0.36 [0.19-0.68]
Serum Osteocalcin (ng/ml)# 29.27 [19.52-43.88]
Vertebral fractures (Yes/No/na) 214/937/40
Hip fractures (Yes/No/na) 29/1,158/4
Data are presented as arithmetic mean ± standard deviation or as 
#geometric mean [± standard deviation range]BMC Medical Genetics 2009, 10:145 http://www.biomedcentral.com/1471-2350/10/145
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success rate, and the genotyping error rate was assessed by
sequencing 384 control and 384 hyperglycemic partici-
pants and by re-genotyping a random 10% sample. No
difference was found with the first genotyping results;
thus, the genotyping error rate was estimated to be 0%.
Statistical analysis
Multivariate linear regression models, taking into account
age and BMI, were performed for testing the association
between rs7595412 and osteoporosis quantitative traits.
Osteocalcin and crosslaps levels were log-transformed
before analysis to obtain normality and symmetry of var-
iances. All P values were two-sided. R statistics (version
2.6.1) software was used for general statistical analysis.
Results
The clinical characteristics of the 1,191 postmenopausal
Danish women are presented in Table 1. We genotyped all
of them for the rs7595412 SNP and identified 943 A/A,
229 A/G and 19 G/G subjects (Table 2). The genotypic dis-
tribution was in Hardy-Weinberg equilibrium (p = 0.24).
The PLCL1 polymorphism was associated neither with hip
BS nor with spine BS variations (Table 2). Furthermore, a
BMD test measuring the mineral density (such as calcium)
in the distal part of the arm, femur neck, total femur, total
spine was performed (Table 2). No association between
the rs7595412 SNP and BMD levels was found. Serum
osteocalcin and crosslaps concentrations were also meas-
ured in the studied individuals (Table 2). Women carrying
at least one copy of the A allele had lower levels of osteo-
calcin as compared with those homozygous for the G
allele (A/A + A/G: 29.18 [19.50-43.65] ng/ml vs  G/G:
35.57 [21.47-58.93] ng/ml, p = 0.03) whereas no effect on
Crosslaps was detected. History of vertebral and hip frac-
tures was also recorded (Table 2). Women homozygous
for the A allele were more affected by such fractures than
those carrying at least one copy of the G allele (A/A:
18.8% vs A/G + G/G: 14.9%, p = 0.04) whereas no effect
on hip fractures was observed.
Discussion
Due to its incidence and clinical consequences, oste-
oporosis followed by vertebral, hip, and forearm fractures
represents an outstanding problem of nowadays' health
care. Because of its high mortality rate hip fractures are of
special interest. The proportion of fractures caused by
postmenopausal osteoporosis increases with age. Costs of
examinations and treatment of women with postmeno-
pausal osteoporosis and fractures are also increasing and
represent a significant amount all over the world. Several
risk factors are known in the pathogenesis of osteoporo-
sis, first of all the lack of sufficient calcium and vitamin D
intake, age, circumstances known to predispose falling,
but also genetic factors. Osteodensitometry by DXA is
among the most important method to evaluate oste-
oporosis, since decrease in BMD, defined as the ratio of
the bone mineral content to BS, strongly correlates with
fracture incidence. Hip BS, as such, was also found to be a
valuable marker for hip fracture [11-20]. Recently, a
genome-wide association study identified the rs7595412
SNP (minor allele frequency = 11.7%), located in the
PLCL1 locus, as strongly associated with hip BS variation
in 50-year-old subjects [34].
Table 2: rs7595412 SNP effects on osteoporosis traits in postmenopausal Danish women






N9 4 3 2 2 9 1 9 n a n a n a
Hip Bone Size
(cm2)
36.5 ± 3.6 36.4 ± 3.7 35.9 ± 4.0 0.26 0.47 0.30
Spine Bone Size
(cm2)
58.3 ± 5.3 58.1 ± 5.0 57.6 ± 6.2 0.49 0.57 0.55
Bone Mineral Density
(g/cm2)
Distal part of the arm 0.358 ± 0.077 0.367 ± 0.072 0.335 ± 0.064 0.45 0.12 0.18
Femur Neck 0.667 ± 0.105 0.666 ± 0.101 0.658 ± 0.075 0.44 0.62 0.47
Total Femur 0.791 ± 0.122 0.784 ± 0.131 0.757 ± 0.083 0.16 0.19 0.24
Total Spine 0.880 ± 0.149 0.890 ± 0.164 0.843 ± 0.122 0.94 0.24 0.66
Serum Crosslaps
(ng/ml)#
0.359 [0.189-0.684] 0.351 [0.187-0.658] 0.457 [0.230-0.905] 0.68 0.10 0.97
Serum Osteocalcin
(ng/ml)#
29.19 [19.51-43.67] 29.12 [19.46-43.59] 35.57 [21.47-58.93] 0.36 0.03 0.71
Vertebral fractures
(Yes/No/na)
177/729/37 34/192/3 3/16/0 na na 0.04
Hip fractures
(Yes/No/na)
23/917/3 6/222/1 0/19/0 na na 0.91
Data are presented as arithmetic mean ± standard deviation or as #geometric mean [± standard deviation range]
p-values are from linear or logistic regression models adjusted for BMI and age
na: a low number of women homozygous for the G allele have had vertebral or hip fracturesBMC Medical Genetics 2009, 10:145 http://www.biomedcentral.com/1471-2350/10/145
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In the present study of postmenopausal Danish women
who were 20 years older, we did not observe such associ-
ation (minor allele frequency = 11.2%). Women over 65
years of age are at particular risk to develop osteoporosis
which may partly explain this lack of association. The age-
related changes in bone size after the menopause caused
by endocortical resorption and periosteal bone apposi-
tion have been shown to occur especially in postmeno-
pausal women with increased bone loss [10] but this
point is still under debate [41]. The PLCL1 genetic varia-
tion was also nominally associated with lower levels of
serum osteocalcin. Markers of bone resorption, like Cross-
laps, are usually elevated in postmenopausal women with
osteoporosis as compared with normal postmenopausal
women, but the markers of bone formation, like osteocal-
cin, are much less elevated and may indeed be decreased
[42,43]. This pattern of changes in bone turnover suggests
that an extent of imbalance of bone resorption and bone
formation occurs in osteoporosis [44]. Serum levels of
osteocalcin were previously found to be either lower
[45,46], similar [47,48] or even slightly elevated [49,50]
in patients with postmenopausal osteoporosis than in the
control subjects. In their study, Liu and colleagues did not
find any effect of PLCL1 SNPs on hip and spine BMD [34].
We confirmed the lack of effect on spine BMD and found
no association with femur BMD. However, Liu and col-
leagues found marginally significant association of the
PLCL1 SNPs with spine BS [34]. We did not observe any
effect on spine BS but our results suggest an effect on the
backbone since the proportion of vertebral fractures was
slightly higher in postmenopausal women homozygous
for the rs7595412 A allele than in the other subjects. At
menopause, bone turnover increases, leading to poorer
bone quality and if the increased bone resorption is not
balanced with bone formation, the risk of fracture
increases too [51]. Given the low proportion of hip frac-
tures in our study samples, we could not correctly assess
the impact of the PLCL1 rs7595412 polymorphism on
this phenotype.
Our analyses were hypothesis-driven, based on previous
studies, and therefore not adjusted for multiple testing.
However, false positive results cannot be excluded, so fur-
ther studies using a large number of samples are necessary
to confirm what was observed on vertebral fractures and
serum osteocalcin levels. Furthermore, fine-mapping and
functional analyses may help to identify etiologic poly-
morphisms in the PLCL1 gene which may have a higher
impact on hip BS and related phenotypes.
Conclusions
In postmenopausal women, our results suggest that the
PLCL1 rs7595412 polymorphism has no obvious effect
on hip BS and BMD but may be associated with increased
proportion of vertebral fracture and increased levels of
osteocalcin.
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